Browse News
Filter News
Found 196 articles
-
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033
4/3/2024
According to the latest research by Nova One Advisor, the global biotechnology market size was valued at USD 1.54 Trillion in 2023 and is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% from 2024 to 2033
-
Exscientia Business and Financial Update for the Full Year 2023
3/21/2024
Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT.
-
Knowing that you want to integrate AI is one thing—but how do you actually do it? For biotech companies kickstarting their generative AI journey, here are four things to consider.
-
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
3/14/2024
Company to host conference call and webcast on March 21, 2024, at 12:30 p.m. GMT / 8:30 a.m. EDT.
-
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
-
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
3/12/2024
Rallybio Corporation today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent program and corporate developments.
-
Anagenex Expands Leadership Team with Appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer
3/4/2024
Anagenex today announced the appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer.
-
Exscientia to Present at Upcoming Investor Conferences in March - February 28, 2024
2/28/2024
Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March.
-
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
2/7/2024
Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company’s deep learning, single-cell precision medicine platform and actual patient clinical response.
-
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
2/6/2024
Rallybio Corporation announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116.
-
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
1/4/2024
Rallybio Corporation provided an update on recent accomplishments and announced expected 2024 milestones.
-
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
12/21/2023
Exscientia plc announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration.
-
The new fund brings Pivotal bioVenture Partners’ total capital to $689 million, which the venture capital firm intends to pump into young biotechs developing “innovative and impactful therapeutics.”
-
Artificial Intelligence Could Speed Drug Discovery Market in Upcoming Years
12/7/2023
The global AI in drug discovery market size will hit around USD 15.44 billion by 2032 and growing at a CAGR of 29.66% from 2023 to 2032.
-
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
12/5/2023
Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing.
-
Precision Oncology Market Size is Valued to Soar USD 258.35 Billion by 2032
12/5/2023
The global precision oncology market size was estimated to grow from USD 100.06 billion in 2022 and is valued to soar USD 258.35 billion by 2032, at an expanding CAGR of 9.9% between 2023 and 2032.
-
In the latest example of big pharma entering AI collaborations or using AI-based tools, AstraZeneca’s deal with Absci will aim to produce an oncology candidate.
-
The pharma giant is paying $9 million upfront to Phenomic AI to develop targets for stroma-rich cancers, some of the hardest cancers to treat, utilizing its single-cell RNA computing platform.
-
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
11/21/2023
Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT).
-
Artificial Intelligence (AI) in Biopharmaceutical Market Size To Surpass USD 14.07 Bn By 2032
11/20/2023
The global artificial intelligence (AI) in biopharmaceutical market size was valued at USD 0.86 billion in 2022 and is projected to surpass around USD 14.07 billion by 2032, expanding at a remarkable CAGR of 32.3% from 2023 to 2032.